BiotechTubeBiotechTube
Home/Intellia Therapeutics/Derek Hicks
DH

Derek Hicks

Senior Vice President, General Counsel and Secretary

Intellia Therapeutics

Therapeutic Areas

Genetic DiseasesOncologyAutoimmune DiseasesRare Diseases

Intellia Therapeutics Pipeline

DrugIndicationPhase
NTLA-2001Transthyretin (ATTR) Amyloidosis with CardiomyopathyPhase 3
NTLA-2002Hereditary Angioedema (HAE)Phase 2
NTLA-3001Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung DiseasePhase 1/2
NTLA-5001Acute Myeloid Leukemia (AML)Phase 1/2
NTLA-6001CD30+ LymphomasPreclinical
NTLA-4001Glycogen Storage Disease Type Ia (GSDIa)Research/Preclinical

Leadership Team at Intellia Therapeutics

JL
John Leonard
President and Chief Executive Officer
LS
Laura Sepp-Lorenzino
Executive Vice President and Chief Scientific Officer
GG
Glenn Goddard
Executive Vice President and Chief Financial Officer
DL
David Lebwohl
Executive Vice President and Chief Medical Officer
AB
Andrew B. Finn
Executive Vice President, Product Development & Operations
NB
Nessan Bermingham
Executive Vice President, Corporate Strategy & External Innovation
JB
James B. Chung
Senior Vice President, Regulatory Affairs & Quality Assurance
DB
David B. Singer
Chairman of the Board of Directors
CS
Carrie S. Cox
Board Member
FV
Frank Verwiel
Board Member
View full Intellia Therapeutics profile